Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ettinger, Neil
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis May 2024 - Aug 2024 : Topline data for IPF Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF	Recruiting	3	576	Canada, US	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	06/25	06/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1667	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	10/25	10/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis	Recruiting	3	698	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Progressive Pulmonary Fibrosis, Interstitial Lung Disease	11/27	11/27
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy	Completed	2	190	Canada, US	SUVN-G3031, Samelisant, Placebo	Suven Life Sciences Limited	Narcolepsy	06/23	06/23
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF Jul 2023 - Dec 2023 : Interim data for the treatment of IPF Initiation of trial in idiopathic pulmonary fibrosis Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis	Active, not recruiting	2	129	Europe, US, RoW	BBT-877, Placebo	Bridge Biotherapeutics, Inc.	Idiopathic Pulmonary Fibrosis	01/25	09/25